tiprankstipranks
Advertisement

CBLS - ETF AI Analysis

Compare

Top Page

CBLS

Changebridge Capital Long/Short Equity ETF (CBLS)

Rating:67Neutral
Price Target:
CBLS, the Changebridge Capital Long/Short Equity ETF, has a solid overall rating driven mainly by strong positions in companies like Lam Research, Vertiv, KLA, and Krystal Biotech, which benefit from robust financial performance, positive earnings calls, and growth tied to advanced technologies and international expansion. These strengths are partly offset by weaker holdings such as Oscar Health and Curaleaf, where profitability, cash flow, and valuation concerns weigh on the fund, and investors should also note the risk that several key holdings face high valuation and regulatory or regional challenges.
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year and in recent months, showing positive momentum.
High-Performing Tech Holdings
Several major technology positions, including chip and semiconductor-related names, have shown strong performance and are helping drive returns.
Focused Sector Exposure
A meaningful tilt toward technology and consumer-related companies gives the fund exposure to areas of the market that have been performing well.
Negative Factors
Very High Expense Ratio
The fund charges a much higher fee than many other ETFs, which can eat into investor returns over time.
Concentration in a Few Stocks and Sectors
A large share of assets is tied up in a handful of technology names and related sectors, increasing the impact if these areas stumble.
Heavy U.S. Market Dependence
With most of its holdings in U.S. companies and very limited foreign exposure, the ETF is highly sensitive to the U.S. stock market’s ups and downs.

CBLS vs. SPDR S&P 500 ETF (SPY)

CBLS Summary

CBLS is the Changebridge Capital Long/Short Equity ETF, which uses an active, hedge-fund-style strategy rather than tracking a set index. It invests mainly in U.S. stocks across many sectors, with a big focus on technology. The fund can buy companies it expects to rise and also bet against stocks it expects to fall. Well-known holdings include Alphabet (Google’s parent company) and Broadcom. Someone might invest for potential growth and diversification, since it can try to profit in both rising and falling markets. A key risk is that this complex strategy is still a stock fund, so its value can go up and down significantly.
How much will it cost me?The Changebridge Capital Long/Short Equity ETF (CBLS) has an expense ratio of 1.9%, which means you’ll pay $19 per year for every $1,000 invested. This is higher than average because it is actively managed, employing a hedge fund-like strategy to navigate complex markets and optimize returns.
What would affect this ETF?The Changebridge Capital Long/Short Equity ETF (CBLS) could benefit from growth in the technology sector, which makes up a significant portion of its holdings, as well as strong performance from top companies like Microsoft and Nvidia. However, rising interest rates or economic slowdowns could negatively impact consumer cyclical and financial sectors, which are also key exposures for the fund. Additionally, regulatory changes or geopolitical tensions affecting North American markets could pose risks to its U.S.-focused investments.

CBLS Top 10 Holdings

CBLS is leaning heavily into U.S. tech, with chip-equipment names like Lam Research and KLA doing much of the heavy lifting, even if KLA has recently lost a bit of steam. Corning adds another steady tech pillar, while Vertiv has been a standout, riding the data-center and AI wave. On the energy side, Schlumberger and Halliburton are quietly pulling their weight, giving the fund a solid oilfield backbone. Venture Global and Oscar Health are more mixed, adding some drama to an otherwise tech-and-energy-driven story.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
10.10%$5.84M
Snowflake3.18%$1.84M$88.57B33.30%
54
Neutral
Micron2.91%$1.68M$1.10T954.70%
79
Outperform
Celestica2.84%$1.64M$44.26B265.70%
73
Outperform
Marvell2.64%$1.52M$179.33B256.97%
76
Outperform
Eos Energy Enterprises2.59%$1.50M$2.86B116.14%
56
Neutral
Oscar Health2.57%$1.48M$6.70B61.08%
49
Neutral
10x Genomics2.55%$1.48M$3.59B213.12%
60
Neutral
Akamai2.55%$1.47M$21.74B102.19%
73
Outperform
Tenable Holdings2.51%$1.45M$3.11B-8.94%
61
Neutral

CBLS Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
31.20
Positive
100DMA
30.53
Positive
200DMA
29.23
Positive
Market Momentum
MACD
0.53
Negative
RSI
68.44
Neutral
STOCH
83.64
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CBLS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.55, equal to the 50-day MA of 31.20, and equal to the 200-day MA of 29.23, indicating a bullish trend. The MACD of 0.53 indicates Negative momentum. The RSI at 68.44 is Neutral, neither overbought nor oversold. The STOCH value of 83.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBLS.

CBLS Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$57.83M1.89%
67
Neutral
$96.53M0.65%
71
Outperform
$94.62M0.89%
71
Outperform
$93.48M0.85%
74
Outperform
$92.16M0.75%
69
Neutral
$87.26M0.52%
73
Outperform
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CBLS
Changebridge Capital Long/Short Equity ETF
34.14
5.96
21.15%
YALL
God Bless America ETF
BAMD
Brookstone Dividend Stock ETF
STNC
Stance Equity ESG Large Cap Core ETF
SOVF
Sovereign's Capital Flourish Fund
RFDA
RiverFront Dynamic US Dividend Advantage ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement